Galectin Therapeutics (GALT) Short Interest Ratio & Short Volume $1.37 +0.12 (+9.60%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Galectin Therapeutics Short Interest DataGalectin Therapeutics (GALT) has a short interest of 8.36 million shares, representing 19.17% of the float (the number of shares available for trading by the public). This marks a 5.96% increase in short interest from the previous month. The short interest ratio (days to cover) is 33.9, indicating that it would take 33.9 days of the average trading volume of 316,484 shares to cover all short positions.Current Short Interest8,360,000 sharesPrevious Short Interest7,890,000 sharesChange Vs. Previous Month+5.96%Dollar Volume Sold Short$11.20 millionShort Interest Ratio33.9 Days to CoverLast Record DateApril 15, 2025Outstanding Shares63,180,000 sharesFloat Size43,620,000 sharesShort Percent of Float19.17%Today's Trading Volume156,085 sharesAverage Trading Volume316,484 sharesToday's Volume Vs. Average49% Short Selling Galectin Therapeutics? Sign up to receive the latest short interest report for Galectin Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGALT Short Interest Over TimeGALT Days to Cover Over TimeGALT Percentage of Float Shorted Over Time Galectin Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20258,360,000 shares $11.20 million +6.0%19.2%33.9 $1.34 3/31/20257,890,000 shares $9.63 million -3.2%18.1%28.4 $1.22 3/15/20258,150,000 shares $13.69 million +0.4%18.9%12.8 $1.68 2/28/20258,120,000 shares $12.75 million +5.2%18.9%11.3 $1.57 2/15/20257,720,000 shares $10.89 million -3.3%18.0%10.6 $1.41 1/31/20257,980,000 shares $9.98 million -2.2%18.5%11.2 $1.25 1/15/20258,160,000 shares $10.44 million +1.5%18.9%11.8 $1.28 12/31/20248,040,000 shares $10.37 million -2.8%18.5%12.1 $1.29 12/15/20248,270,000 shares $17.45 million +41.1%19.0%16.7 $2.11 11/30/20245,860,000 shares $16.94 million +2.8%13.5%26.7 $2.89 Get the Latest News and Ratings for GALT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/20245,700,000 shares $15.79 million +3.3%13.1%40.3 $2.77 10/31/20245,520,000 shares $13.63 million +1.1%12.8%42.9 $2.47 10/15/20245,460,000 shares $14.20 million +1.5%12.6%45 $2.60 9/30/20245,380,000 shares $14.80 million +2.3%12.4%43.7 $2.75 9/15/20245,260,000 shares $15.10 million +4.0%12.2%30.9 $2.87 8/31/20245,060,000 shares $13.64 million +1.0%11.7%29.8 $2.70 8/15/20245,010,000 shares $10.97 million +6.4%11.6%30.3 $2.19 7/31/20244,710,000 shares $11.78 million +3.1%10.9%26.7 $2.50 7/15/20244,570,000 shares $10.88 million +14.0%10.7%24 $2.38 6/30/20244,010,000 shares $9.06 million +1.5%9.4%18 $2.26 6/15/20243,950,000 shares $10.35 million +3.4%9.3%20.3 $2.62 5/31/20243,820,000 shares $10.39 million +2.4%9.0%20.2 $2.72 5/15/20243,730,000 shares $11.41 million +19.6%8.8%20.4 $3.06 4/30/20243,120,000 shares $10.95 million +13.9%7.4%18.8 $3.51 4/15/20242,740,000 shares $10.71 million +21.8%6.5%18.7 $3.91 3/31/20242,250,000 shares $5.38 million +5.1%5.3%21.3 $2.39 3/15/20242,140,000 shares $4.41 million +1.9%5.1%29.4 $2.06 2/29/20242,100,000 shares $4.11 million +1.0%5.0%30.6 $1.96 2/15/20242,080,000 shares $3.64 million No Change4.9%33.3 $1.75 1/31/20242,080,000 shares $3.52 million -0.5%4.9%32.8 $1.69 1/15/20242,090,000 shares $3.85 million -1.0%5.0%34 $1.84 12/31/20232,110,000 shares $3.50 million -0.9%5.0%33.8 $1.66 12/15/20232,130,000 shares $3.41 million +1.0%5.0%33.7 $1.60 11/30/20232,110,000 shares $4.11 million +8.2%5.0%36.9 $1.95 11/15/20231,950,000 shares $3.65 million No Change4.6%37.3 $1.87 10/31/20231,950,000 shares $3.98 million +3.7%4.7%39.3 $2.04 10/15/20231,880,000 shares $3.78 million -5.5%4.5%35.9 $2.01 9/30/20231,990,000 shares $3.82 million -1.5%4.8%36.1 $1.92 9/15/20232,020,000 shares $3.56 million No Change4.8%40.3 $1.76 8/31/20232,020,000 shares $3.54 million +2.5%4.8%35.7 $1.75Virtually Limitless Energy? (Ad)A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.One company’s discovery could change power forever 8/15/20231,970,000 shares $3.15 million -3.4%4.7%32.2 $1.60 7/31/20232,040,000 shares $3.06 million -1.5%4.8%33.6 $1.50 7/15/20232,070,000 shares $3.37 million -3.3%4.9%35 $1.63 6/30/20232,140,000 shares $3.08 million +2.9%5.1%37.4 $1.44 6/15/20232,080,000 shares $3.04 million -0.5%4.9%35.4 $1.46 5/31/20232,090,000 shares $3.28 million -1.4%5.0%40.3 $1.57 5/15/20232,120,000 shares $3.48 million +0.5%5.0%29.1 $1.64 4/30/20232,110,000 shares $3.71 million No Change5.0%22.8 $1.76 4/15/20232,110,000 shares $4.24 million No Change5.0%21.6 $2.01 3/31/20232,110,000 shares $4.43 million -0.5%5.0%21.4 $2.10 3/15/20232,120,000 shares $4.03 million +5.0%5.0%18.5 $1.90 2/28/20232,020,000 shares $4.18 million No Change4.8%17.2 $2.07 2/15/20232,020,000 shares $2.91 million +3.1%4.8%20.5 $1.44 1/31/20231,960,000 shares $2.27 million -1.5%4.6%19.7 $1.16 1/15/20231,990,000 shares $2.27 million -0.5%4.7%24.8 $1.14 12/30/20222,000,000 shares $2.26 million -1.5%4.7%22.7 $1.13 12/15/20222,030,000 shares $2.35 million +0.5%4.8%26.6 $1.16 11/30/20222,020,000 shares $2.57 million -0.5%4.8%32.8 $1.27 11/15/20222,030,000 shares $2.52 million -1.5%4.8%33.7 $1.24 10/31/20222,060,000 shares $2.84 million -3.7%4.9%33.9 $1.38 10/15/20222,140,000 shares $3.47 million +3.4%5.0%29.6 $1.62 9/30/20222,070,000 shares $3.37 million No Change4.9%29.8 $1.63 9/15/20222,070,000 shares $3.71 million -1.4%4.9%26.7 $1.79 8/31/20222,100,000 shares $3.99 million -1.4%4.9%24.9 $1.90 8/15/20222,130,000 shares $4.64 million -0.5%5.0%22.6 $2.18 7/31/20222,140,000 shares $4.84 million +0.9%5.0%21.4 $2.26 7/15/20222,120,000 shares $3.50 million -2.8%5.0%22.5 $1.65 6/30/20222,180,000 shares $2.86 million -1.8%5.1%19.7 $1.31 6/15/20222,220,000 shares $2.82 million +3.7%6.5%18.9 $1.27 5/31/20222,140,000 shares $2.76 million -1.4%5.0%18.8 $1.29 5/15/20222,170,000 shares $2.95 million -9.6%5.1%19.7 $1.36 4/30/20222,400,000 shares $3.72 million +7.6%5.6%23 $1.55 4/15/20222,230,000 shares $3.88 million +9.9%5.2%19.8 $1.74 3/31/20222,030,000 shares $3.27 million +2.5%4.8%20.1 $1.61 3/15/20221,980,000 shares $3.45 million +7.0%4.6%17.6 $1.74 2/28/20221,850,000 shares $3.46 million -5.6%4.3%14.7 $1.87 2/15/20221,960,000 shares $4.06 million -1.0%4.6%14.5 $2.07 1/31/20221,980,000 shares $3.82 million No Change4.6%12.7 $1.93 1/15/20221,980,000 shares $4.00 million +4.2%4.6%12.5 $2.02 12/31/20211,900,000 shares $3.93 million -11.6%4.4%11.8 $2.07 12/15/20212,150,000 shares $4.84 million -4.4%5.0%12.4 $2.25 11/30/20212,250,000 shares $5.92 million -1.8%5.3%11.2 $2.63 11/15/20212,290,000 shares $6.55 million +5.5%5.4%9.3 $2.86 10/29/20212,170,000 shares $6.88 million -11.4%5.1%8 $3.17 10/15/20212,450,000 shares $8.26 million +3.8%5.7%6.9 $3.37 9/30/20212,360,000 shares $9.16 million -13.9%5.5%4.7 $3.88 9/15/20212,740,000 shares $10.22 million -7.4%6.4%1.3 $3.73 8/31/20212,960,000 shares $11.63 million -18.2%7.0%1.3 $3.93 8/13/20213,620,000 shares $12.24 million +17.5%8.5%1.6 $3.38 7/30/20213,080,000 shares $8.47 million -9.9%7.4%1.4 $2.75Virtually Limitless Energy? (Ad)A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.One company’s discovery could change power forever 7/15/20213,420,000 shares $8.86 million +25.7%8.2%1.3 $2.59 6/30/20212,720,000 shares $8.70 million -40.6%6.5%0.7 $3.20 6/15/20214,580,000 shares $16.03 million +11.2%11.0%1.8 $3.50 5/28/20214,120,000 shares $16.36 million -22.9%10.0%1.6 $3.97 5/14/20215,340,000 shares $22.48 million -2.2%12.9%2.1 $4.21 4/30/20215,460,000 shares $23.15 million +12.4%13.4%2.2 $4.24 4/15/20214,860,000 shares $11.47 million +1.9%12.0%2.3 $2.36 3/31/20214,770,000 shares $9.68 million +2.4%11.8%7.7 $2.03 3/15/20214,660,000 shares $10.76 million +0.7%11.5%14.8 $2.31 2/26/20214,630,000 shares $10.60 million -0.9%11.4%14.4 $2.29 2/12/20214,670,000 shares $11.25 million +3.6%11.5%15.1 $2.41 1/29/20214,510,000 shares $8.93 million -0.4%11.1%15.9 $1.98 1/15/20214,530,000 shares $10.10 million -5.0%11.2%18.8 $2.23 12/31/20204,770,000 shares $10.97 million -3.3%11.8%21.3 $2.30 12/15/20204,930,000 shares $12.47 million -2.2%12.2%15.3 $2.53 11/30/20205,040,000 shares $13.36 million -2.0%12.4%16.2 $2.65 11/15/20205,140,000 shares $14.14 million -1.7%12.7%17.2 $2.75 10/30/20205,230,000 shares $13.65 million -2.2%12.9%17 $2.61 10/15/20205,350,000 shares $14.77 million +0.8%13.2%17.5 $2.76 9/30/20205,310,000 shares $14.18 million +4.1%13.0%18.8 $2.67 9/15/20205,100,000 shares $14.94 million -3.8%12.5%29.7 $2.93 8/31/20205,300,000 shares $14.05 million -1.3%13.0%30.8 $2.65 8/14/20205,370,000 shares $16.49 million -2.2%13.1%30.2 $3.07 7/31/20205,490,000 shares $14.33 million -1.4%13.4%29.8 $2.61 7/15/20205,570,000 shares $15.32 million +0.4%13.6%22.7 $2.75 6/30/20205,550,000 shares $16.87 million +1.7%13.6%21.2 $3.04 6/15/20205,460,000 shares $15.07 million -0.4%13.3%21.4 $2.76 5/29/20205,480,000 shares $16.17 million -0.5%13.4%19.5 $2.95 5/15/20205,510,000 shares $15.65 million -1.6%13.5%18.5 $2.84 GALT Short Interest - Frequently Asked Questions What is Galectin Therapeutics' current short interest? Short interest is the volume of Galectin Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 8,360,000 shares of GALT short. 19.17% of Galectin Therapeutics' shares are currently sold short. Learn More on Galectin Therapeutics' current short interest. What is a good short interest ratio for Galectin Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GALT shares currently have a short interest ratio of 34.0. Learn More on Galectin Therapeutics's short interest ratio. Which institutional investors are shorting Galectin Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Galectin Therapeutics: FNY Investment Advisers LLC, Wolverine Trading LLC, LMR Partners LLP, Group One Trading LLC, Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Boothbay Fund Management LLC, HAP Trading LLC, Concourse Financial Group Securities Inc., Affinity Asset Advisors LLC, and ADAR1 Capital Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Galectin Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 19.17% of Galectin Therapeutics' floating shares are currently sold short. Is Galectin Therapeutics' short interest increasing or decreasing? Galectin Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 8,360,000 shares, an increase of 6.0% from the previous total of 7,890,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Galectin Therapeutics' float size? Galectin Therapeutics currently has issued a total of 63,180,000 shares. Some of Galectin Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Galectin Therapeutics currently has a public float of 43,620,000 shares. How does Galectin Therapeutics' short interest compare to its competitors? 19.17% of Galectin Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Galectin Therapeutics: Olema Pharmaceuticals, Inc. (13.17%), Benitec Biopharma Inc. (1.24%), COMPASS Pathways plc (7.39%), Alpha Teknova, Inc. (26.65%), Allogene Therapeutics, Inc. (20.67%), Entrada Therapeutics, Inc. (5.00%), Arcturus Therapeutics Holdings Inc. (20.80%), Taysha Gene Therapies, Inc. (11.61%), Heron Therapeutics, Inc. (23.00%), Atyr PHARMA INC (11.66%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Galectin Therapeutics stock? Short selling GALT is an investing strategy that aims to generate trading profit from Galectin Therapeutics as its price is falling. GALT shares are trading up $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Galectin Therapeutics? A short squeeze for Galectin Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GALT, which in turn drives the price of the stock up even further. How often is Galectin Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GALT, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies OLMA Short Interest Data BNTC Short Interest Data CMPS Short Interest Data TKNO Short Interest Data ALLO Short Interest Data TRDA Short Interest Data ARCT Short Interest Data TSHA Short Interest Data HRTX Short Interest Data ATYR Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GALT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
